Mianserine Viatris

Mianserin, the active ingredient in Mianserine Viatris, is a tetracyclic antidepressant presented as an oral tablet. It is indicated for the treatment of major depressive disorder in adult patients, acting on central neurotransmitter pathways to improve mood and affect.

GNH USA supplies Mianserine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The product complies with EU pharmaceutical regulations and is manufactured under GMP conditions, ensuring consistent potency and safety for patients.

Mianserin is a tetracyclic antidepressant used primarily in the management of depressive disorders. - Major depressive disorder: reduces depressive symptoms, improves mood, and enhances functional capacity in adult patients. - Anxiety associated with depression: may help alleviate concomitant anxiety symptoms, contributing to overall treatment response. - Insomnia related to depression: can improve sleep initiation and maintenance, supporting better daytime functioning. - Adjunctive therapy in treatment‑resistant depression: may be considered when first‑line agents are insufficient. - Psychomotor retardation: may improve energy levels and psychomotor speed in depressed patients.

Mianserin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or fatigue. - Weight gain: increase in body weight over time. - Dry mouth: reduced salivation causing oral dryness. - Constipation: infrequent bowel movements. - Dizziness: light‑headed sensation, especially on standing. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Seizures: convulsive episodes. - Anaphylactic reaction: life‑threatening allergic response. - Hepatic dysfunction: liver enzyme abnormalities or failure.

When prescribing Mianserin, clinicians should consider several safety precautions to minimize risk. - Monitor blood pressure: watch for orthostatic hypotension, especially at treatment start. - Assess hepatic function: evaluate liver enzymes before and during therapy. - Use caution in elderly: increased sensitivity to sedative effects and falls. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Review concomitant CNS depressants: adjust dosing if combined with alcohol or sedatives. - Store at ambient temperature: keep tablets in original packaging, protect from moisture.

Mianserin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis or serotonin syndrome. - SSRIs or other serotonergic agents: increased risk of serotonin syndrome. - Tricyclic antidepressants: additive effects on cardiac conduction and sedation.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance drowsiness and impair coordination. - Antihypertensive drugs: potential for additive blood pressure lowering. - CYP2D6 inhibitors (e.g., fluoxetine): may increase Mianserin plasma levels. - Anticholinergic agents: heightened anticholinergic burden leading to constipation or confusion.